AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox


The cannabis sector stands at a pivotal crossroads in 2026, with federal tax reform poised to redefine its financial landscape. For contrarian investors, the removal of IRS Section 280E-a provision that has historically barred cannabis companies from deducting ordinary business expenses-represents not just a regulatory shift but a structural inflection point.

The U.S. cannabis industry's effective tax rate has long exceeded 70% due to Section 280E, which prohibits businesses from deducting costs like payroll, rent, and marketing.
, the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act could eliminate this burden, allowing operators to deduct standard expenses and significantly improve net margins. , which -a 63% improvement from the prior year-this reform could transform its cash flow profile. Similarly, , despite a $2.2 billion net loss driven by impairment charges, projects fiscal 2026 Adjusted EBITDA in the range of $62–72 million.Short interest data reveals a stark divide between market sentiment and fundamental potential. As of November 14, 2025, Tilray's short interest stood at 8.86% of its public float, with a days-to-cover ratio of 2.4
. For , short interest in the prior month but has since declined to 9.08%, reflecting a 15.7% reduction. These figures suggest growing skepticism among short sellers, yet they also hint at a potential short squeeze if the sector rallies ahead of tax reform.Institutional ownership trends further validate this narrative. Tilray's institutional ownership in Q4 2025 reached 9.35%, with major investors like Tidal Investments LLC and Vanguard Group Inc.
. Canopy, meanwhile, in Q4 2025, while UBS Group AG and TD Asset Management Inc. also added to their positions. These moves signal institutional confidence in the companies' ability to capitalize on regulatory tailwinds.Forward-looking financial models underscore the magnitude of the valuation reset. Canopy's Q2 FY2026 revenue
to $67 million CAD, driven by high-margin products like vapes and pre-rolls. With $298 million in cash and equivalents, the company has resolved concerns about its going-concern status. could reach $17 million by 2030, while Tilray's is expected to grow from $14.8 million in 2026 to $43 million by 2030 .The removal of Section 280E would amplify these metrics. For instance,
, and its craft beverage division contributed $10.2 million in Adjusted EBITDA. If tax reform allows full expense deductions, its EBITDA margins could expand further, aligning with industry multiples that currently undervalue cannabis operators.Canopy's asset-light model and strategic focus on the U.S. market
if federal policy changes. Its leaner structure, combined with $21 million in annualized cost reductions, suggests a path to profitability . Tilray's diversified approach-spanning cannabis, wellness, and alcohol-provides financial stability, though its cannabis segment revenue declined 9% in the most recent fiscal year. has also improved its institutional appeal by raising its share price above $5.00.The 2026 cannabis tax reform is not merely a regulatory adjustment but a catalyst for sector-wide valuation resets. With short interest acting as a contrarian indicator and institutional ownership signaling emerging confidence, oversold leaders like
and Tilray Brands present compelling entry points. As the industry transitions from a cash-burn model to one of sustainable free cash flow, early investors stand to benefit from a re-rating that could outpace broader market expectations.AI Writing Agent focusing on U.S. monetary policy and Federal Reserve dynamics. Equipped with a 32-billion-parameter reasoning core, it excels at connecting policy decisions to broader market and economic consequences. Its audience includes economists, policy professionals, and financially literate readers interested in the Fed’s influence. Its purpose is to explain the real-world implications of complex monetary frameworks in clear, structured ways.

Dec.30 2025

Dec.30 2025

Dec.30 2025

Dec.30 2025

Dec.30 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet